NeOncoFRAx is an organization focused on developing personalized, tumor-specific cancer vaccines. We work closely with Erasmus MC and other partners to make innovative immunotherapies accessible to patients.

Our initial focus is on pancreatic cancer, but our technology allows us to focus on other solid tumors in the future.

We analyze tumor and blood samples from the patient to identify unique mutations (neoantigens). Based on these, we design and produce a vaccine that specifically activates the patient's immune system against the tumor.

We strive to balance patient benefit with socially responsible pricing and have no commercial shareholders. Our mission is to make treatments broadly accessible, with socially responsible pricing.

The process includes: collecting tumor and blood samples, DNA/RNA sequencing, bioinformatics analysis for neoantigen discovery, peptide synthesis, vaccine formulation, and administration under medical supervision.

The entire process from sample collection to vaccine production usually takes several weeks, depending on logistics and laboratory capacity.

We share the latest news, clinical study updates, and future scientific publications through our website.

You can support us through strategic or philanthropic partnerships, joint research projects, or by contacting our management via the contact page.